Skip to content
Subscriber Only

Myriad Gene Patent Ruling Triggers Race for Cancer Tests

Companies and a university are moving to offer cheaper and broader genetic testing for breast cancer risk to a growing group of women, following a U.S. Supreme Court ruling that ended Myriad Genetics Inc.’s monopoly over DNA that vastly raises odds for the disease.

Within hours of the decision, the University of Washington and Ambry Genetics, a closely held company in Aliso Viejo, California, said they would immediately offer expanded testing that included the BRCA1 and BRCA2 genes, which Myriad has had under patent since the late 1990s. Quest Diagnostics Inc. said it would sell testing for the genes later this year.